^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Adenocarcinoma

    Related cancers:
    Apply
    Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients (ZANGEA) (NCT07176312)
    Phase 2
    Institut für Klinische Krebsforschung IKF GmbH ...
    Not yet recruiting
    Last update posted :
    09/16/2025
    Initiation :
    10/01/2025
    Primary completion :
    03/01/2029
    Completion :
    03/01/2029
    PD-L1
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • Ziihera (zanidatamab-hrii)
    Obeticholic Acid for Prevention in Barrett's Esophagus (NCT04939051)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/03/2024
    Primary completion :
    09/29/2025
    Completion :
    09/29/2026
    FGF19 • SOX2 • CASP3 • FGF • CDX2
    A Study of SGN-B6A in Advanced Solid Tumors (SGNB6A-001) (NCT04389632)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    06/08/2020
    Primary completion :
    11/30/2026
    Completion :
    02/28/2028
    HER-2
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)
    Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab (M21-404) (NCT05029882)
    Phase 1
    AbbVie
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/13/2021
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    MET
    |
    MET amplification • EGFR wild-type
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)
    A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors (NCT05836324)
    Phase 1
    Incyte Corporation
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    07/24/2023
    Primary completion :
    12/24/2026
    Completion :
    12/24/2026
    HER-2 • BRAF • ER • PGR • ROS1
    |
    HER-2 negative • ER negative
    |
    INCA33890
    A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01) (NCT05152147)
    Phase 3
    Jazz Pharmaceuticals
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/02/2021
    Primary completion :
    05/15/2025
    Completion :
    05/15/2026
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)
    A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus (NCT06056024)
    Phase 1
    Boehringer Ingelheim
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    12/06/2023
    Primary completion :
    05/26/2027
    Completion :
    05/26/2027
    KRAS
    |
    KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification
    Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors (D9750C00001) (NCT06005493)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    07/11/2023
    Primary completion :
    12/16/2026
    Completion :
    12/16/2026
    CLDN18
    |
    CLDN18.2 positive • CLDN1 positive
    |
    AZD5863
    Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours (NCT05427487)
    Phase 1
    ImmVirx Pty Ltd
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    02/17/2023
    Primary completion :
    09/30/2026
    Completion :
    11/30/2026
    MSI
    |
    Tyvyt (sintilimab) • IVX037
    TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (NCT05862324)
    Phase 1/2
    Triumvira Immunologics, Inc.
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    08/23/2023
    Primary completion :
    08/01/2027
    Completion :
    08/01/2027
    EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA
    |
    EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2
    A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) (KEYNOTE-F21) (NCT04225117)
    Phase 2
    Astellas Pharma Global Development, Inc.
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    03/09/2020
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    BRAF • ER • ALK • PGR
    |
    PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA (NCT05299476)
    Phase 2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    04/16/2022
    Primary completion :
    01/20/2025
    Completion :
    06/01/2025
    HER-2 • PD-L1
    |
    HER-2 negative
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin